Comparison Chart Ribomic Inc.

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-10 EDT			5-day change	1st Jan Change
74.00 ^JPY	-3.90%		+12.12%	-5.13%

07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
07-01	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	RIBOMIC INC.	Bio Therapeutic Drugs	-3.90%	+12.12%	-5.13%	-37.82%	-77.58%	26.53M